Evidence map›Paper›PMID 39866330›Full record

ArticleACG case reports journal2025

Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.

Albert Z Huang, Hyun Jae Kim, Billy Zhao, Daniel R Owen, Avni Jain, Daljeet Chahal, Eric M Yoshida

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Albert Z HuangDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Hyun Jae KimDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.
Billy ZhaoDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-5436-2432
Daniel R OwenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Avni JainDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.
Daljeet ChahalDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.
Eric M YoshidaDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel immunotherapy for the treatment of refractory malignancies. While various complications have been described previously, sclerosing cholangitis has not been reported. We report the first description of sclerosing cholangitis secondary to Tecartus CAR-T therapy in a 67-year-old man with refractory stage IV mantle cell lymphoma. As CAR-T therapy becomes increasingly used in clinical practice, it is critical to recognize potential hepatobiliary complications. Further research is needed to facilitate early diagnosis and to develop effective treatment strategies for managing these rare but severe complications.

Indexed as

CAR-TcholangiopathycholangitisERCPlymphoma

Identifiers

PMID39866330
PMCPMC11759319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.